Recombinant Therapeutics and Biotechnology in Diabetes Treatment
- 1. Department of Botany, Holy Cross College (Autonomous), Nagercoil-4, Tamilnadu, India. (Affiliated to Manonmaniam Sundaranar University, Abishekapatti, Tirunelveli Distrist - Pin 627001.
- 2. Agricultural College and Research Institute, Tamil Nadu Agricultural University (TNAU), Coimbatore, Tamilnadu, India.
- 3. Department of Biomedical Sciences, Noorul Islam Centre for Higher Education, Kumaracoil, Tamilnadu, India.
Description
Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from impaired insulin secretion, insulin action, or both. The global prevalence of diabetes has increased significantly, creating an urgent need for effective and safe therapeutic strategies. Biotechnology has played a major role in transforming diabetes management, particularly through the development of recombinant therapeutics such as human insulin, insulin analogues, and recombinant proteins that improve glycemic control. Recombinant DNA technology, protein engineering, gene therapy, and stem cell research have contributed to advances in diabetes treatment by improving drug efficacy, safety, and delivery. Modern biotechnological approaches also focus on developing long-acting insulin, glucose-responsive insulin systems, and regenerative therapies aimed at restoring pancreatic β-cell function. This chapter discusses the role of recombinant therapeutics and biotechnology in diabetes treatment, highlighting recent developments and future prospects in this rapidly evolving field
Files
6. Albino Wins. J.pdf
Files
(303.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:e87d51e24c982bd5f83e65850c9d72a4
|
303.9 kB | Preview Download |
Additional details
References
- 1. American Diabetes Association. (2023). Standards of care in diabetes. Diabetes Care, 46(Supplement 1), S1–S291. 2. Baeshen, M. N., Baeshen, N. A., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014). Cell factories for insulin production. Microbial Cell Factories, 13, 141. 3. Chen, S., & Wang, J. (2020). Advances in recombinant protein therapeutics for diabetes. Biotechnology Advances, 39, 107465. 4. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., & Shulman, G. I. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1, 15019. 5. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., & others. (2023). Pharmacologic approaches to glycemic treatment. Diabetes Care, 46(Supplement 1), S140–S157. 6. Hirsch, I. B. (2018). Insulin analogues. New England Journal of Medicine, 378(2), 174–183. 7. Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes. The Lancet, 383(9922), 1068–1083. 8. Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals. Nature Reviews Drug Discovery, 13(9), 655–672. 9. Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of insulin action and resistance. Physiological Reviews, 98(4), 2133–2223. 10. Shapiro, A. M. J., Thompson, D., Donner, T. W., Bellin, M. D., Hsueh, W., & others. (2017). Insulin-producing cells from stem cells. Cell Stem Cell, 20(2), 137–138. 11. Walsh, G. (2018). Biopharmaceutical benchmarks. Nature Biotechnology, 36(12), 1136–1145. 12. Zhang, Y., & Liao, L. (2021). Nanotechnology-based insulin delivery systems. Journal of Controlled Release, 330, 1055–1070.